Skip to main content

Closed

NRIX: Nurix Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+53.9% / yr

Operating margin-982.4%

ROIC-77.3%

Financially safe

Stretched

Debt / equity0.14×

Interest coverage0.0×

Current ratio6.34×

Nurix Therapeutics, Inc.

NRIXNASDAQ·USD·Closed

Nurix Therapeutics, Inc.

NRIXNASDAQ·USD·Closed

$23.21

−1.57%

$23.21

−$0.37 (1.57%)

52W Range

89thpctl

Volume

0.37×avg

Mkt Cap

2.41BUSD

P/E

-6.7TTM

Div Yield

–ann

52W Range

89thpctl

Volume

0.37×avg

Market Cap

2.41BUSD

P/E Ratio

-6.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings